Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor

PURPOSE: BRAF mutations promote melanoma cell proliferation and survival primarily through activation of MEK. The purpose of this study was to determine the response rate (RR) for the selective, allosteric MEK1/MEK2 inhibitor trametinib (GSK1120212), in patients with metastatic BRAF-mutant melanoma....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Kim, Kevin B., Kefford, Richard, Pavlick, Anna C., Infante, Jeffrey R., Ribas, Antoni, Sosman, Jeffrey A., Fecher, Leslie A., Millward, Michael, McArthur, Grant A., Hwu, Patrick, Gonzalez, Rene, Ott, Patrick A., Long, Georgina V., Gardner, Olivia S., Ouellet, Daniele, Xu, Yanmei, DeMarini, Douglas J., Le, Ngocdiep T., Patel, Kiran, Lewis, Karl D.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2013
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4878037/
https://ncbi.nlm.nih.gov/pubmed/23248257
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.43.5966
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados